Beyond NSCLC, Ma et al.73examined the neurological safety of PD-L1 inhibitor-based combination therapy in 46 patients with extensive-stage small cell lung cancer (ES-SCLC). This evidence concerns the gene CD274 and non-small cell lung carcinoma.